169 related articles for article (PubMed ID: 37294384)
21. Invasive mucinous adenocarcinoma of the lung: clinicopathological features,
Sun X; Zeng B; Tan X; Chen Z; Pan X; Jiang L
Ann Nucl Med; 2023 Mar; 37(3):198-207. PubMed ID: 36538165
[TBL] [Abstract][Full Text] [Related]
22. Prognosis in Resected Invasive Mucinous Adenocarcinomas of the Lung: Related Factors and Comparison with Resected Nonmucinous Adenocarcinomas.
Lee HY; Cha MJ; Lee KS; Lee HY; Kwon OJ; Choi JY; Kim HK; Choi YS; Kim J; Shim YM
J Thorac Oncol; 2016 Jul; 11(7):1064-73. PubMed ID: 27016260
[TBL] [Abstract][Full Text] [Related]
23. NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma.
Duruisseaux M; McLeer-Florin A; Antoine M; Alavizadeh S; Poulot V; Lacave R; Rabbe N; Cadranel J; Wislez M
Cancer Med; 2016 Dec; 5(12):3579-3585. PubMed ID: 27770508
[TBL] [Abstract][Full Text] [Related]
24. MUC5AC enhances tumor heterogeneity in lung adenocarcinoma with mucin production and is associated with poor prognosis.
Dong Y; Zhou L; Zhao D; Li K; Liu Z; Che N; Liu H
Jpn J Clin Oncol; 2020 Jun; 50(6):701-711. PubMed ID: 32083303
[TBL] [Abstract][Full Text] [Related]
25. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.
Cserepes M; Ostoros G; Lohinai Z; Raso E; Barbai T; Timar J; Rozsas A; Moldvay J; Kovalszky I; Fabian K; Gyulai M; Ghanim B; Laszlo V; Klikovits T; Hoda MA; Grusch M; Berger W; Klepetko W; Hegedus B; Dome B
Eur J Cancer; 2014 Jul; 50(10):1819-1828. PubMed ID: 24768329
[TBL] [Abstract][Full Text] [Related]
26. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.
Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163
[TBL] [Abstract][Full Text] [Related]
27. Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinoma.
Kishikawa S; Hayashi T; Saito T; Takamochi K; Kohsaka S; Sano K; Sasahara N; Sasa K; Kurihara T; Hara K; Suehara Y; Takahashi F; Suzuki K; Yao T
Mod Pathol; 2021 Apr; 34(4):786-797. PubMed ID: 33024306
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological and genetic analyses of pulmonary enteric adenocarcinoma.
Okada F; Takeda M; Fujii T; Uchiyama T; Sasaki S; Matsuoka M; Nitta Y; Terada C; Maebo K; Morita K; Ishida E; Sawabata N; Ohbayashi C
J Clin Pathol; 2024 Jan; 77(2):111-115. PubMed ID: 36456172
[TBL] [Abstract][Full Text] [Related]
29. Mucinous lung adenocarcinoma, particularly referring to EGFR-mutated mucinous adenocarcinoma.
Wakejima R; Inamura K; Ninomiya H; Nagano H; Mun M; Okumura S; Okubo K; Ishikawa Y
Pathol Int; 2020 Feb; 70(2):72-83. PubMed ID: 31859434
[TBL] [Abstract][Full Text] [Related]
30. GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.
Ritterhouse LL; Vivero M; Mino-Kenudson M; Sholl LM; Iafrate AJ; Nardi V; Dong F
Mod Pathol; 2017 Dec; 30(12):1720-1727. PubMed ID: 28776576
[TBL] [Abstract][Full Text] [Related]
31. Invasive mucinous adenocarcinoma of the lung.
Xu L; Li C; Lu H
Transl Cancer Res; 2019 Dec; 8(8):2924-2932. PubMed ID: 35117050
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics of patients with KRAS mutation detected by liquid biopsy.
Amino Y; Low SK; Ninomiya H; Kiritani A; Miyadera K; Kakuto S; Akita T; Tsugitomi R; Ariyasu R; Uchibori K; Kitazono S; Yanagitani N; Nishio M
Thorac Cancer; 2023 Nov; 14(33):3317-3322. PubMed ID: 37751775
[TBL] [Abstract][Full Text] [Related]
33. KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.
Krasinskas AM; Chiosea SI; Pal T; Dacic S
Mod Pathol; 2014 Feb; 27(2):262-70. PubMed ID: 23887294
[TBL] [Abstract][Full Text] [Related]
34. [Construction of a Prognostic Prediction Model of Patients with Pathologic N0
in Resected Invasive Mucinous Adenocarcinoma of the Lung].
Wang Z; He J; Shen H; Chen X; Lin C; Yu H; Gao J; He X; Shen W
Zhongguo Fei Ai Za Zhi; 2024 Jan; 27(1):47-55. PubMed ID: 38296625
[TBL] [Abstract][Full Text] [Related]
35. Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy.
Bironzo P; Cani M; Jacobs F; Napoli VM; Listì A; Passiglia F; Righi L; Di Maio M; Novello S; Scagliotti GV
Cancer; 2023 Jun; 129(11):1662-1671. PubMed ID: 36905392
[TBL] [Abstract][Full Text] [Related]
36. Retrospective Data Analysis of Patients With Metastatic Lung Adenocarcinoma With or Without
Moeller M; Schaedlich F; Schuette W
Cancer Control; 2022; 29():10732748221126949. PubMed ID: 36355617
[TBL] [Abstract][Full Text] [Related]
37. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
38. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
39. Prognostic analysis of primary mucin-producing adenocarcinoma of the lung: a comprehensive retrospective study.
Qu Y; Zhao D; Mu J; Che N; Zhang C; Liu Z; Su D; Zhou L; Zhang H; Wei L
Tumour Biol; 2016 Jan; 37(1):887-96. PubMed ID: 26254613
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological features of lung adenocarcinoma with KRAS mutations.
Kakegawa S; Shimizu K; Sugano M; Miyamae Y; Kaira K; Araki T; Nakano T; Kamiyoshihara M; Kawashima O; Takeyoshi I
Cancer; 2011 Sep; 117(18):4257-66. PubMed ID: 21387273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
